---
pmid: '21575865'
title: Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS
  gene fusion-positive prostate cancer.
authors:
- Brenner JC
- Ateeq B
- Li Y
- Yocum AK
- Cao Q
- Asangani IA
- Patel S
- Wang X
- Liang H
- Yu J
- Palanisamy N
- Siddiqui J
- Yan W
- Cao X
- Mehra R
- Sabolch A
- Basrur V
- Lonigro RJ
- Yang J
- Tomlins SA
- Maher CA
- Elenitoba-Johnson KS
- Hussain M
- Navone NM
- Pienta KJ
- Varambally S
- Feng FY
- Chinnaiyan AM
journal: Cancer Cell
year: '2011'
full_text_available: false
pmcid: PMC3113473
doi: 10.1016/j.ccr.2011.04.010
---

# Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.
**Authors:** Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM
**Journal:** Cancer Cell (2011)
**DOI:** [10.1016/j.ccr.2011.04.010](https://doi.org/10.1016/j.ccr.2011.04.010)
**PMC:** [PMC3113473](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113473/)

## Abstract

1. Cancer Cell. 2011 May 17;19(5):664-78. doi: 10.1016/j.ccr.2011.04.010.

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene 
fusion-positive prostate cancer.

Brenner JC(1), Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, 
Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, 
Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, 
Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM.

Author information:
(1)Michigan Center for Translational Pathology, University of Michigan, 1400 E. 
Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA.

Erratum in
    Cancer Cell. 2013 Apr 15;23(4):557.

Comment on
    Cancer Cell. 2011 May 17;19(5):573-4. doi: 10.1016/j.ccr.2011.05.003.

Recurrent fusions of ETS genes are considered driving mutations in a diverse 
array of cancers, including Ewing's sarcoma, acute myeloid leukemia, and 
prostate cancer. We investigate the mechanisms by which ETS fusions mediate 
their effects, and find that the product of the predominant ETS gene fusion, 
TMPRSS2:ERG, interacts in a DNA-independent manner with the enzyme poly 
(ADP-ribose) polymerase 1 (PARP1) and the catalytic subunit of DNA protein 
kinase (DNA-PKcs). ETS gene-mediated transcription and cell invasion require 
PARP1 and DNA-PKcs expression and activity. Importantly, pharmacological 
inhibition of PARP1 inhibits ETS-positive, but not ETS-negative, prostate cancer 
xenograft growth. Finally, overexpression of the TMPRSS2:ERG fusion induces DNA 
damage, which is potentiated by PARP1 inhibition in a manner similar to that of 
BRCA1/2 deficiency.

Copyright Â© 2011 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ccr.2011.04.010
PMCID: PMC3113473
PMID: 21575865 [Indexed for MEDLINE]
